Contrasting Immunome (NASDAQ:IMNM) & PDS Biotechnology (NASDAQ:PDSB)

Immunome (NASDAQ:IMNM) and PDS Biotechnology (NASDAQ:PDSB) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Immunome and PDS Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-57.61%	-52.39%
PDS Biotechnology	N/A	-241.95%	-90.36%

Volatility and Risk

Immunome has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.

Insider and Institutional Ownership

44.6% of Immunome shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 7.2% of Immunome shares are held by insiders. Comparatively, 9.2% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Immunome and PDS Biotechnology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94 million	362.11	-$212.39 million	($2.42)	-9.17
PDS Biotechnology	N/A	N/A	-$34.50 million	($0.75)	-1.52

PDS Biotechnology has lower revenue, but higher earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Immunome and PDS Biotechnology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1	0	9	1	2.91
PDS Biotechnology	1	0	2	0	2.33

Immunome presently has a consensus price target of $33.45, indicating a potential upside of 50.76%. PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 689.47%. Given PDS Biotechnology’s higher possible upside, analysts plainly believe PDS Biotechnology is more favorable than Immunome.

Summary

Immunome beats PDS Biotechnology on 8 of the 13 factors compared between the two stocks.

About Immunome

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.